Holen Sie sich die Stockscreener-App
42.56
3.38%
1.415
Schlusskurs vom Vortag:
$41.15
Offen:
$41.87
24-Stunden-Volumen:
771.56K
Relative Volume:
0.61
Marktkapitalisierung:
$4.04B
Einnahmen:
$47.30M
Nettoeinkommen (Verlust:
$-225.97M
KGV:
-18.11
EPS:
-2.35
Netto-Cashflow:
$-188.86M
1W Leistung:
+11.61%
1M Leistung:
+36.57%
6M Leistung:
-1.37%
1J Leistung:
+375.31%
1-Tages-Spanne:
$40.88
$42.95
1-Wochen-Bereich:
$36.91
$42.95
52-Wochen-Spanne:
$6.76
$46.98
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Firmenname
Scholar Rock Holding Corp
Sektor
Branche
Telefon
857-259-3860
Adresse
301 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie SRRK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
42.56 | 3.51B | 47.30M | -225.97M | -188.86M | -2.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.82 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
551.07 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.04 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
570.72 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
288.93 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-26 | Bestätigt | H.C. Wainwright | Buy |
| 2024-10-07 | Bestätigt | H.C. Wainwright | Buy |
| 2024-03-28 | Eingeleitet | Raymond James | Strong Buy |
| 2023-10-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-04-03 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-07-12 | Eingeleitet | Truist | Buy |
| 2022-03-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-22 | Herabstufung | Jefferies | Buy → Hold |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-06 | Eingeleitet | JP Morgan | Overweight |
| 2020-03-12 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Scholar Rock Holding Corp Aktie (SRRK) Neueste Nachrichten
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives $42.67 Average PT from Brokerages - MarketBeat
What makes Scholar Rock Holding Corporation stock price move sharplyFree AI-Powered Stock Predictions - Newser
How Scholar Rock Holding Corporation stock performs during market volatilityCapital Preservation Investment Ideas - Newser
Why Scholar Rock Holding Corporation stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser
Scholar Rock (NASDAQ:SRRK) Trading Up 6.5%What's Next? - MarketBeat
Scholar Rock CSO Mo Qatanani sells $828,898 in shares By Investing.com - Investing.com Nigeria
Scholar Rock CSO Mo Qatanani sells $828,898 in shares - Investing.com Australia
Insider Sell: Mo Qatanani Sells 24,066 Shares of Scholar Rock Ho - GuruFocus
Scholar Rock Q1 2025 slides: apitegromab advances toward FDA approval with priority review - Investing.com Nigeria
Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 3000E Value Index - MarketScreener
Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Jeffrey S. Flier Sells 20,316 Shares - MarketBeat
Truist reiterates buy rating on Scholar Rock stock amid SMA therapy potential - Investing.com Nigeria
Is Scholar Rock Holding Corp. overvalued or undervalued? - MarketsMojo
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Abbott Laboratories (ABT) - The Globe and Mail
Scholar Rock's Breakthrough SMA Drug Shows Positive Phase 3 Results, FDA Fast-Tracks Review - Stock Titan
Scholar Rock (NASDAQ:SRRK) Trading Down 5.7% – Time to Sell? - Defense World
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
The Globe’s stars and dogs for the week - The Globe and Mail
Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial - Insider Monkey
Scholar Rock (NASDAQ:SRRK) Receives Outperform Rating from Wedbush - MarketBeat
Why Scholar Rock Shares Are Soaring Today - The Globe and Mail
Scholar Rock (NASDAQ:SRRK) Shares Gap UpWhat's Next? - MarketBeat
Transcript : Scholar Rock Holding CorporationSpecial Call - MarketScreener
Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results - Yahoo Finance
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study - Benzinga
Scholar Rock stock soars after drug shows promise in preserving lean mass during weight loss - Investing.com Australia
Trading Day Triumph: Scholar Rock Holding Corp (SRRK) Ends at 31.15, a -3.05 Surge/Plunge - DWinneX
Scholar Rock's drug helps Zepbound patients retain more muscle in trial - marketscreener.com
Scholar Rock (SRRK) Surges 14% Following EMBRAZE Trial Results | SRRK Stock News - GuruFocus
Scholar Rock (SRRK) Surges After Promising Weight Loss Trial - GuruFocus
Scholar Rock Reports Positive Results From Phase 2 EMBRAZE Study - Nasdaq
Scholar Rock stock gains on weight loss data (SRRK:NASDAQ) - Seeking Alpha
Scholar Rock (SRRK) Reveals Phase 2 Trial Success of Apitegromab with Tirzepatide | SRRK Stock News - GuruFocus
Scholar Rock's drug helps patients on Zepbound preserve muscle in trial - MarketScreener
Scholar Rock’s apitegromab preserves lean mass during weight loss - Investing.com
Scholar Rock's drug helps preserve lean mass in mid-stage trial - marketscreener.com
Scholar Rock's Breakthrough Drug Shows 55% Better Muscle Preservation in Weight Loss Study - Stock Titan
Scholar Rock’s apitegromab preserves lean mass during weight loss By Investing.com - Investing.com Nigeria
Notable Two Hundred Day Moving Average CrossSRRK - Nasdaq
Scholar Rock Holding Corp Executives Sell Shares to Cover Tax Obligations - TradingView
GAMMA Investing LLC Buys 30,140 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) - MarketBeat
GAMMA Investing LLC Has $962,000 Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Rhumbline Advisers Purchases 7,491 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased By Stocktwits - Investing.com India
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Scholar Rock at Goldman Sachs Conference: Strategic Focus on SMA By Investing.com - Investing.com Nigeria
Transcript : Scholar Rock Holding Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 09 - MarketScreener
Truist Financial Sticks to Its Buy Rating for Nurix Therapeutics (NRIX) - The Globe and Mail
Scholar Rock Holding Co. (NASDAQ:SRRK) Stake Increased by California State Teachers Retirement System - MarketBeat
Finanzdaten der Scholar Rock Holding Corp-Aktie (SRRK)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
2.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):